ArticleNature communications2019
Hepatic arginase 2 (Arg2) is sufficient to convey the therapeutic metabolic effects of fasting.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Isolation and identification of a chicken-derived Salmonella phage VB-SalS-XND03, Its biological characteristics and application effect against Salmonella infection in chicks.Poultry science · 2026Article
- Metabolite profiling of the effect of prenatal stimuli across postnatal treatments in the liver.Molecular and cellular endocrinology · 2026Article
- ROS-responsive Ganoderma lucidum polysaccharide nanocomposite targeting prosenescent oxidative stress niche for structural and functional diabetic tendon regeneration.Journal of nanobiotechnology · 2026Article
- Osteopontin: a central hub in the pathogenesis and therapeutic intervention of liver disease.Annals of medicine · 2025Review
- Dimorphic regulation of time-restricted feeding effects by hepatocyte Period 1.Molecular metabolism · 2025Article
- Review
- Lactate transporter MCT4 regulates the hub genes for lipid metabolism and inflammation to attenuate intracellular lipid accumulation in non-alcoholic fatty liver disease.Genes & diseases · 2025Article
- Synthesis of Arginase Inhibitors: An Overview.Pharmaceutics · 2025Review
- Hepatocyte Period 1 dictates oxidative substrate selection independent of the core circadian clock.Cell reports · 2024Article
- Hepatocyte MMP14 mediates liver and inter-organ inflammatory responses to diet-induced liver injury.PNAS nexus · 2024Article
- Location Matters: Mitochondrial Arginase 2 as a Treatment for Metabolic Disease?Cellular and molecular gastroenterology and hepatology · 2024Article
- Macrophage-derived Osteopontin (SPP1) Protects From Nonalcoholic Steatohepatitis.Gastroenterology · 2023Article
- The tetraspanin transmembrane protein CD53 mediates dyslipidemia and integrates inflammatory and metabolic signaling in hepatocytes.The Journal of biological chemistry · 2023Article
- SIRT1 selectively exerts the metabolic protective effects of hepatocyte nicotinamide phosphoribosyltransferase.Nature communications · 2022Article
- SIRT1 selectively exerts the metabolic protective effects of hepatocyte nicotinamide phosphoribosyltransferase.Nature communications · 2022Article
- Individual and joint effects of trehalose and glutamate on diabetic retinopathy: a propensity score-matched case-control study.Endocrine connections · 2022Article
- Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism.Cell reports. Medicine · 2022Article
- Functions of regulators of G protein signaling 16 in immunity, inflammation, and other diseases.Frontiers in molecular biosciences · 2022Review
- GDF15 negatively regulates RGS16 to impair hepatic lipid metabolism in male mice offspring conceived by in vitro fertilization.American journal of translational research · 2022Article
- Calorie Restriction as a New Treatment of Inflammatory Diseases.Advances in nutrition (Bethesda, Md.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Caloric restriction and intermittent fasting are emerging therapeutic strategies against obesity, insulin resistance and their complications. However, the effectors that drive this response are not completely defined. Here we identify arginase 2 (Arg2) as a fasting-induced hepatocyte factor that protects against hepatic and peripheral fat accumulation, hepatic inflammatory responses, and insulin and glucose intolerance in obese murine models. Arg2 is upregulated in fasting conditions and upon treatment with the hepatocyte glucose transporter inhibitor trehalose. Hepatocyte-specific Arg2 overexpression enhances basal thermogenesis, and protects from weight gain, insulin resistance, glucose intolerance, hepatic steatosis and hepatic inflammation in diabetic mouse models. Arg2 suppresses expression of the regulator of G-protein signalling (RGS) 16, and genetic RGS16 reconstitution reverses the effects of Arg2 overexpression. We conclude that hepatocyte Arg2 is a critical effector of the hepatic glucose fasting response and define a therapeutic target to mitigate the complications of obesity and non-alcoholic fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.